Daniel Skovronsky

Daniel Skovronsky is the chief scientific officer and executive vice president of science and technology at Eli Lilly and Company, where he also serves as president of Lilly Research Laboratories and Lilly Immunology. Skovronsky oversees global business development and leads research efforts for the pharmaceutical company, guiding the development of treatments for Alzheimer’s disease, obesity, and cancer. He has contributed to the approval of drugs including tirzepatide for weight loss and donanemab for Alzheimer’s, as well as antibody therapies for COVID-19.

Skovronsky began his career as the founder and CEO of Avid Radiopharmaceuticals, where he developed diagnostic technology for early detection of Alzheimer’s disease. After Avid was acquired by Eli Lilly, he transitioned into senior roles at the company, including chief medical officer and senior vice president of clinical and product development. Skovronsky has been recognized in the life sciences industry, with honors such as inclusion in the STAT STATUS List and TIME100 Health.

Skovronsky has guided Eli Lilly through scientific milestones and public health challenges, including the development of COVID-19 antibody treatments. He is a frequent speaker at industry events and conventions, sharing insights on drug development, regulatory strategy, and biomedical research. Skovronsky’s career reflects leadership and a commitment to advancing global health through science.